Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: an overview - PubMed

Affiliations

• PMID: 18845418
• DOI: 10.1016/j.ridd.2008.08.007

Review

Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: an overview

Johnny L Matson et al. Res Dev Disabil. 2009 May-Jun.

Abstract

Challenging behaviors in persons with intellectual disabilities are primary target for treatment in mental health clinics and institutions. Furthermore, an increasing number of people are receiving psychotropic medications for the management of their challenging behaviors. Many people are often treated with high doses of multiple psychotropic medications for extended periods of time with little or no data collected to determine treatment efficacy. Similarly, data demonstrating treatment effectiveness is at best questionable at this time. It is for these reasons that controversy exists regarding the use of psychotropic medication for challenging behaviors. The purpose of this paper was to summarize past and current studies of drug related interventions for challenging behaviors for persons with intellectual disabilities. Based on the results of this review, the effectiveness of psychotropic medications in managing challenging behaviors is best described as minimal and a need exists for controlled studies of higher scientific quality in this area. Considering alternative psychologically based interventions and careful functional assessments appear to be advisable.

Similar articles

• Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature.

  Deb S, Unwin GL. Deb S, et al. Curr Opin Psychiatry. 2007 Sep;20(5):461-6. doi: 10.1097/YCO.0b013e3282ab9952. Curr Opin Psychiatry. 2007. PMID: 17762588 Review.

• The use of risperidone among individuals with mental retardation: clinically supported or not?

  Singh AN, Matson JL, Cooper CL, Dixon D, Sturmey P. Singh AN, et al. Res Dev Disabil. 2005 May-Jun;26(3):203-18. doi: 10.1016/j.ridd.2004.07.001. Res Dev Disabil. 2005. PMID: 15668072 Review.

• The use of clozapine among individuals with intellectual disability: a review.

  Singh AN, Matson JL, Hill BD, Pella RD, Cooper CL, Adkins AD. Singh AN, et al. Res Dev Disabil. 2010 Nov-Dec;31(6):1135-41. doi: 10.1016/j.ridd.2010.07.003. Epub 2010 Aug 8. Res Dev Disabil. 2010. PMID: 20692809 Review.

• Designs and analyses of psychotropic and behavioral interventions for the treatment of problem behavior among people with intellectual and developmental disabilities.

  Courtemanche AB, Schroeder SR, Sheldon JB. Courtemanche AB, et al. Am J Intellect Dev Disabil. 2011 Jul;116(4):315-28. doi: 10.1352/1944-7558-116.4.315. Am J Intellect Dev Disabil. 2011. PMID: 21740259 Review.

• Rational use and rationale for use: psychiatric medication at an Argentine institution for intellectual disability.

  de Menil V, Cohen A. de Menil V, et al. Transcult Psychiatry. 2009 Dec;46(4):651-71. doi: 10.1177/1363461509351377. Transcult Psychiatry. 2009. PMID: 20028682

Cited by

• Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice.

  Paton C, Bhatti S, Purandare K, Roy A, Barnes T. Paton C, et al. BMJ Open. 2016 Dec 5;6(12):e013116. doi: 10.1136/bmjopen-2016-013116. BMJ Open. 2016. PMID: 27920085 Free PMC article.

• Drug burden index to define the burden of medicines in older adults with intellectual disabilities: An observational cross-sectional study.

  O'Connell J, Burke É, Mulryan N, O'Dwyer C, Donegan C, McCallion P, McCarron M, Henman MC, O'Dwyer M. O'Connell J, et al. Br J Clin Pharmacol. 2018 Mar;84(3):553-567. doi: 10.1111/bcp.13479. Epub 2018 Jan 5. Br J Clin Pharmacol. 2018. PMID: 29193284 Free PMC article.

• Aligning quality of life and guidelines for off-label psychotropic drugs in adults with intellectual disabilities and challenging behaviour.

  Laermans P, Morisse F, Lombardi M, Gérard S, Vandevelde S, de Kuijper G, Audenaert K, Claes C. Laermans P, et al. Int J Dev Disabil. 2023 May 17;69(3):398-413. doi: 10.1080/20473869.2023.2195721. eCollection 2023. Int J Dev Disabil. 2023. PMID: 37213586 Free PMC article.

• Effectiveness of lifestyle interventions for improving the physical health of children and adolescents taking antipsychotic medications: protocol for a systematic review and meta-analysis.

  Hawker P, Bellamy J, McHugh C, Wong TY, Williams K, Wood A, Anderson V, Tonge BJ, Ward P, Sciberras E, Bellgrove MA, Silk T, Lin PI, Eapen V. Hawker P, et al. BMJ Open. 2023 Oct 27;13(10):e073893. doi: 10.1136/bmjopen-2023-073893. BMJ Open. 2023. PMID: 37890972 Free PMC article.

• Risk factors of acute behavioral regression in psychiatrically hospitalized adolescents with autism.

  Périsse D, Amiet C, Consoli A, Thorel MV, Gourfinkel-An I, Bodeau N, Guinchat V, Barthélémy C, Cohen D. Périsse D, et al. J Can Acad Child Adolesc Psychiatry. 2010 May;19(2):100-8. J Can Acad Child Adolesc Psychiatry. 2010. PMID: 20467546 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal